Day: November 2, 2023

Btab Ecommerce Group Announces Plans To Empower US Resellers With Access To Australian Made Product Lines

Written by Customer Service on November 2, 2023. Posted in Public Companies.

‘Btab set to boost opportunities for US sellers, expanding lines with quality Australian goods’. SYDNEY, Australia, Nov. 02, 2023 (GLOBE NEWSWIRE) — Btab Ecommerce Group, Inc. (OTC: BBTT) (the “Company”) has unveiled its latest plans to support small and medium size businesses to flourish in the super-brand dominated niches, by leveraging the power of the Btab network to connect US resellers with Australian made product ranges. The move will see significant numbers of US-based resellers of all sizes provided with open access to a broad range of high-quality product lines from Australia, provided either through Btab manufacturing facilities or via partnerships with thousands of high-quality Australian providers. Recognized worldwide for in-demand health and beauty product lines, the plans will open up access to Australian product...

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

Written by Customer Service on November 2, 2023. Posted in Public Companies.

New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that the Company has received notification by the United States Patent and Trademark Office (“USPTO”) that two additional patents covering FIRDAPSE® (amifampridine) Tablets 10 mg, were allowed and will be granted within the next two months. These new patents are for claims associated with the unique and novel, previously unknown, bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE...

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023. “The poster that we and researchers from the Josep Carreras Leukaemia Research Institute in Barcelona, Spain are presenting at ASH 2023 shows that the study...

Roblon’s full-year guidance for 2022/23 and 2023/24

Written by Customer Service on November 2, 2023. Posted in Public Companies.

The English-language edition of the company Announcement no 13 – 2023 will be published 3rd of November 2023 at www.roblon.com.

St. Louis-Based Non-Profit, Lighthouse for the Blind, Acquires Assets of Falcon Safety Products

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Two Additional Berkeley Facilities Will Be Opened to Support the Acquisition and to Provide More Employment Opportunities for People Who Are Legally Blind ST. LOUIS, Nov. 02, 2023 (GLOBE NEWSWIRE) — The Lighthouse for the Blind (LHB), a not-for-profit organization based in St. Louis that specializes in chemical manufacturing, filling, and packaging, has successfully acquired the assets of Falcon Safety Products located in Branchburg, New Jersey. As part of this acquisition, LHB plans to establish two new facilities in Berkeley, Missouri, with the aim of expanding employment opportunities for individuals who are legally blind. Falcon Safety Products is a reputable manufacturer known for producing compressed-gas dusters and signal horns, including the popular Dust-Off® brand of consumer electronics cleaning accessories. They also...

Tarkett – Number of voting right October 2023

Written by Customer Service on November 2, 2023. Posted in Public Companies.

PARIS, FRANCE, November, 2nd, 2023 – Information on the total number of voting rights and shares in Tarkett’s share capital as of October, 31, 2023 (Article L233-8-II of the French Commercial Code andArticle 223-16 of the General Regulation of the Autorité des marchés financiers)Date Total number of shares in the share capital Total number of voting rightsAs of October 31, 2023 65,550,281 Number of theoretical voting rights: 123 644 811 Number of exercisable voting rights: 123 626 252* * After deduction of the treasury shares without voting rights. *** Investor Relations Contact investors@tarkett.com Media contacts Tarkett – communication@tarkett.com Brunswick – tarkett@brunswickgroup.com – Tel.: +33 (0) 1 53 96 83 83 About Tarkett With a history of 140 years, Tarkett is a worldwide leader in...

Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S

Written by Customer Service on November 2, 2023. Posted in Public Companies.

2 November 2023 Announcement no. 43Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S Pharma Equity Group A/S today held its Extraordinary General Meeting with the following results: 1) Attorney Martin Allan Christensen from Accura Advokatpartnerselskab was elected as chairman at the extraordinary general meeting. 2) The following new candidates were elected to the Board of Directors: (i) Omar S. Qandeel, and (ii) Martin Engell-Rossen. The Board of Director immediately thereafter constituted itself with Christian Vinding Thomsen as the Chairman of the Board of Directors and Martin Engell-Rossen as the Vice Chairman of the Board of Directors. The Board of Directors will thereafter consist of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice Chairman), Omar S. Qandeel, Lars Gundorph and Peter...

Global Automotive Airbag Silicone Market Size to Reach USD 1,301.37 Million in 2032 | Emergen Research

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Increasing installation of airbags in commercial vehicles and increasing passenger vehicle sales and production are some of key factors driving global automotive airbag silicone market growth Vancouver, Nov. 02, 2023 (GLOBE NEWSWIRE) — The global automotive airbag silicone market size reached USD 237.5 Million in 2020 and is expected to register a CAGR of 15.4% during the forecast period, according to latest analysis by Emergen Research. Global automotive airbag silicone market revenue is expected to increase significantly during the forecast period due to increasing installation of airbags in passenger and commercial vehicles. Furthermore, increasing deployment of stringent safety regulations by governments of various countries is expected to further support growth of the global automotive airbag silicone market going ahead. However,...

Global Sports Technology Market Size to Reach USD 79.31 Billion by 2032 | Emergen Research

Written by Customer Service on November 2, 2023. Posted in Mergers And Acquisitions.

Rapid adoption of technologically advanced solutions in all fields of sport is driven by urgent need for recovery across the sports industry post the global COVID-19 lockdown Vancouver, Nov. 02, 2023 (GLOBE NEWSWIRE) — The global sports technology market is projected to reach a market size of USD 79.31 Billion by 2032, according to latest analysis by Emergen Research. This growth can be attributed to increasing adoption of advanced technologies for a range of applications in the world of sports. The COVID-19 pandemic and lockdown has severely impacted the global sports industry as all sporting events and stadiums remained under lockdown. A vast majority of athletes and players have suffered due to inability to train and stay in top shape. As a result, 2021 is a pivotal year for athletes, broadcasters, teams, and fans around the...

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating ZYNLONTA in combination with rituximab in patients with r/r follicular lymphoma LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023. “We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,”...

Day: November 2, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice